久久综合日本久久综合,亚洲成AV人片在线观看天堂无码,国产在线视频不卡一区二区,久久久久看免费高清特色大片

武漢佰樂博生物技術有限公司
   
     
您當前的位置: 網站首頁 > 產品展廳 >試劑盒 >BioSim Cabiralizumab ELISA Kit(KDC25201)
BioSim Cabiralizumab ELISA Kit(KDC25201)
  • 品牌:AntibodySystem
  • 產地:France
  • 型號:96 assays
  • 貨號:KDC25201
  • 發(fā)布日期: 2022-07-25
  • 更新日期: 2024-10-23
產品詳請
產地 France
保存條件 2-8 ℃
品牌 AntibodySystem
貨號 KDC25201
用途 For Research Use Only.
檢測方法 Elisa
CAS編號
保質期 1 year
適應物種 Cabiralizumab
檢測限 0.156 ug /ml
數量 99999
包裝規(guī)格 96 assays
標記物 Unconjugate
純度 95%%
樣本 Plasma, Serum
應用 Elisa
是否進口


Catalog No.

KDC25201

Stability and Storage

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.

Detection method

Colorimetric

Precision

CV<20%

Sample type

Plasma, Serum

Assay type

Quantitative

Sensitivity

0.156 μg/ml

Range

0.31-5 μg/mL

Recovery

80-120%

Specifications

Cabiralizumab

Alternative Names

FPA-008, , CAS: 1613144-80-1

Background

Cabiralizumab (FPA008) is a humanized monoclonal antibody directed against colony stimulating factor-1 receptor (CSF1R), which is a member of the CSF1/PDGF receptor family of tyrosine-protein kinases. The developers of cabiralizumab including Apexigen, Bristol-Myers Squibb, Five Prime Therapeutics, University of Chicago and Yale University. Although it is reported to be designed for the treatment of tenosynovial giant cell tumor, the studies of treatment for pancreatic cancer, pigmented villonodular synovitis, malignant melanoma, non-small cell lung cancer, renal cell carcinoma and solid tumors also have been reported to be undergoing. The trails of pancreatic cancer and pigmented villonodular synovitis are in Phase II, while others are in Phase I. Orphan designation of cabiralizumab had been granted in the United States and European Commission for the treatment of pigmented villonodular synovitis.

Shipping

2-8 ℃

Note

For Research Use Only.


Aiming to develop the most reliable bioreagents, AntibodySystem SAS was founded in 2019 in France by a team of professionals from top industrial companies and research institutes. The collective scientific and technical experiences in our team have brought breaking throughs in multiple product developments, including recombinant antibodies, recombinant proteins, biosimilar, RUO ELISA kits and other related products. By working with talented researchers and technicians, AntibodySystem continues to upgrade product qualities and lower the overall cost, offering accountable and affordable solutions for biolabs all over the world. Since its establishment, AntibodySystem has built long term and stable collaborations with academia, pharmaceutical industry, biotech companies and research hospitals, supporting their R&D by AntibodySystem's bioreagents with excellent data accuracy and reproducibility.




AntibodySystem由具有30多年蛋白抗體開發(fā)經驗的 創(chuàng)立于法國,專注于生命科學和生物制藥領域研究,總部位于法國斯特拉斯堡市。AntibodySystem自主開發(fā)了高效、高產的真核重組表達系統,利用該系統生產了高質量的重組蛋白、抗體產品。目前產品包括藥物靶點蛋白以及對照抗體藥物、Invivo功能性抗體、SAA系列流式抗體、PEG抗體、磷酸化抗體、抗小分子抗體、ADA抗體、PK&ADA ELISA試劑盒。


普健生物作為AntibodySystem在亞洲區(qū)授權 ,致力于為廣大科研工作者提供 的產品服務。

如果您對我們的產品感興趣,請聯系027-65279366。

以上產品僅用于科研,產品信息以產品 為準






聯系方式
手機:18162686757
微信掃一掃
兴城市| 高邮市| 龙陵县| 全椒县| 锦屏县| 延寿县| 凤城市| 太仆寺旗| 闻喜县| 辽宁省| 安岳县| 贵定县| 观塘区| 文水县| 湖南省| 江城| 雷山县| 和静县| 阿克苏市| 沙河市| 大田县| 黄骅市| 吉木萨尔县| 成都市| 沂水县| 武定县| 闽清县| 井研县| 民丰县| 苏州市| 文昌市| 岳阳县| 年辖:市辖区| 武宁县| 句容市| 怀柔区| 舟曲县| 孟津县| 龙江县| 修文县| 克东县|